Sinopharm To Set Up Another Pharmaceutical Logistics Base
This article was originally published in PharmAsia News
Sinopharm has signed an agreement to invest more than RMB 120 million ($17.4 million) to set up a pharmaceutical logistics base in the Hefei Economic and Technological Development Area. With its low logistics costs, Hefei city in central China represents the nation's key transportation hub. The base is scheduled to start construction at the end of this year and will go into operation in 2009. After completion, the project will reach sales levels of RMB 5 billion ($727.6 million). It is poised to provide a standardized, integrated modern public pharmaceutical logistics platform to promote the consolidation of related enterprises in Hefei and its periphery. (Click here for more - Chinese Language)
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.